Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
41.71
+0.28 (+0.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
21
22
Next >
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 28, 2022
By Jad Malaeb, Benzinga
Via
News Direct
Topics
ETFs
Stocks
Exposures
US Equities
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
October 27, 2022
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022.
Via
Benzinga
Biogen To Report Q3 Earnings: Here's What To Expect
October 21, 2022
Biogen will report third-quarter 2022 results on Oct 25, before market open.
Via
Talk Markets
Analyst Bullish On SQZ Biotech's Technology For Solving Cell Therapy Challenges
October 20, 2022
Via
Benzinga
Roche Posts Lower Quarterly Sales As Demand For COVID Products Slide
October 18, 2022
Via
Benzinga
Market Sentiment Improves Amid Earnings Season
October 18, 2022
The fourth quarter started on a sour note as geopolitical tensions and recession fears triggered a risk-averse mood, but earnings season has started since then, focusing market participants’ attention...
Via
Talk Markets
Week In Review: Jemicare Out-Licenses Prostate Cancer Therapy To Roche For $650 Million
October 15, 2022
Deals, financings, trials and approvals on the China biotech/pharma market.
Via
Talk Markets
Analyst Upgrades Biogen Citing Upcoming Conference, Competitive Readouts
October 13, 2022
Stifel upgraded Biogen Inc (NASDAQ: BIIB) from Hold to Buy, saying shares have faded since positive lecanemab data in mild Alzheimer's.
Via
Benzinga
Biogen Soars On Upgrade; Why Lilly, Roche Won't Block Its Alzheimer's Opportunity
October 13, 2022
Even a percentage of the Alzheimer's market could mean $7 billion for Biogen.
Via
Investor's Business Daily
Roche's Muscular Atrophy Treatment Improves Motor Function In Pretreated Patients
October 12, 2022
Via
Benzinga
Roche To Introduce Next-Generation Portfolio Of COVID-19 Rapid Tests
October 12, 2022
Via
Benzinga
Despite Advancement, Benefits From Alzheimer's Drugs May Be Limited, Say Researchers
October 10, 2022
Via
Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
Lineage Cell Therapeutics Inc (NYSE: LCTX) has opened a new research and development facility in Carlsbad, California.
Via
Benzinga
Stock Market Falls, S&P 500 Hits Bear Lows; Biogen, Nike, Micron Are Key Movers: Weekly Review
September 30, 2022
The major indexes fell, with the S&P 500 breaking below bear market lows.
Via
Investor's Business Daily
These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win
September 28, 2022
Via
Benzinga
This Analyst Believes Biogen's Lecanemab Data Not 'Slam Dunk' For Complete CMS Approval
September 28, 2022
Via
Benzinga
2 Sympathy Plays To Watch For In The Wake Of Biogen's Positive Alzheimer's Drug Data
September 28, 2022
Biogen Inc. (NASDAQ: BIIB) and partner Eisai Co. Ltd.
Via
Benzinga
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
September 27, 2022
Via
Benzinga
COVID-19 Complacency Pushes Identification Of New Variants To Back Seat, WHO Warns
September 23, 2022
The World Health Organization (WHO) warned that it struggles to identify and
Via
Benzinga
Multiple Sclerosis Is A Crowded Space, But This Stock Is A Potential 6X Multi-bagger
September 19, 2022
Via
Benzinga
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
September 19, 2022
Via
Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
September 16, 2022
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
September 13, 2022
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Via
Benzinga
A Quick Look At The OTC Markets' Most-Active Securities In August - Here's What You Need to Know
September 12, 2022
While July gave markets around the world a breather, August reestablished 2022’s choppy financial conditions.
Via
Benzinga
No More Free COVID-19 At-Home Tests, Federal Government Says
August 29, 2022
CNBC reported that the federal government is set to suspend its offer of free at-home COVID-19 tests by Friday, September 2, without congressional au
Via
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).
Via
Benzinga
Week In Review: Everest Sells Trodelvy Rights Back To Gilead For $455 Million
August 20, 2022
Shanghai Everest Medicines returned rights for Trodelvy to Immunomedics, now a subsidiary of Gilead Sciences, in an agreement worth up to $455 million ($280 million upfront).
Via
Talk Markets
China-Based Jemincare Inks Prostate Cancer Drug Pact With Roche's Genentech
August 18, 2022
Via
Benzinga
Roche's Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
August 16, 2022
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
21
22
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.